	US 12,292,442 B2
	Monoclonal antibody against CD19 antibody and application thereof
Liang Da, Shanghai (CN)
Assigned to BIOSWAN LABORATORIES, INC., Shanghai (CN)
Appl. No. 17/416,974
Filed by BIOSWAN LABORATORIES, INC., Shanghai (CN)
PCT Filed Dec. 17, 2019, PCT No. PCT/CN2019/126087 § 371(c)(1), (2) Date Jun. 21, 2021, PCT Pub. No. WO2020/125653, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 201811565418.1 (CN), filed on Dec. 20, 2018.
Prior Publication US 2022/0074937 A1, Mar. 10, 2022
Int. Cl. G01N 33/569 (2006.01); C07K 16/28 (2006.01); C07K 16/42 (2006.01)

CPC G01N 33/56972 (2013.01) [C07K 16/2803 (2013.01); C07K 16/4258 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

11 Claims

1. An antibody having:

(1) a heavy chain variable region comprising the following three complementarity determining regions or CDRs:

CDR1 as shown in SEQ ID NO: 3;

CDR2 as shown in SEQ ID NO: 4; and

CDR3 as shown in SEQ ID NO: 5; and

(2) a light chain variable region comprising the following three complementarity determining regions or CDRs:

CDR1′ as shown in SEQ ID NO: 6;

CDR2′ as shown in SEQ ID NO: 7; and

CDR3′ as shown in SEQ ID NO: 8;

wherein the antibody is specific against a CD19-binding antibody, and the CD19-binding antibody is a murine monoclonal antibody FMC63 or FMC63 scFv.